{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:21:29Z","timestamp":1781828489395,"version":"3.54.5"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1308,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>Population-based quantitative data on the mortality and cancer incidence of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC) are scarce. Our aim was to systematically investigate the survival and risk of malignancy on population-based cohorts of AIH, PBC, and PSC in Canterbury, New Zealand. Multiple case-finding methods were employed, including searches of all public and private, adult and pediatric outpatient clinics, hospital notes, laboratory, radiology, and pathology reports. Cases that fulfilled standardized diagnostic criteria were included. Kaplan-Meier survival estimates, standardized mortality ratios (SMR), and standard incidence ratios (SIR) for malignancy were calculated. A total of 130 AIH, 70 PBC, and 81 PSC patients were included contributing to 1,156, 625, and 613 person-years at risk, respectively. For AIH, PBC, and PSC cohorts, SMRs for all-cause mortality were 2.1 (95% confidence interval [CI] 1.4-3.1), 2.7 (95% CI 1.7-4.0), and 4.1 (95% CI 2.6-6.3), SMRs for hepatobiliary mortality were 42.3 (95% CI 20.3-77.9), 71.2 (95% CI 30.7-140.3), and 116.9 (95% CI 66.8-189.8), SIRs for all cancers were 3.0 (95% CI 2.0-4.3), 1.6 (95% CI 0.8-2.9), and 5.2 (95% CI 3.3-7.8), and SIRs for extrahepatic malignancy were 2.7 (95% CI 1.8-3.9), 1.6 (95% CI 0.8-2.9), and 3.0 (95% CI 1.6-5.1), respectively.<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion :<\/jats:title>\n            <jats:p>\n                                 <jats:bold>This is the first population-based study to examine and compare the survival and cancer incidence in AIH, PBC, and PSC in the same population. The mortality for all three cohorts was significantly increased due to liver-related death, demonstrating the inadequacy of current management strategies. The risk of hepatic and extrahepatic malignancy was significantly increased in AIH and PSC patients. (Hepatology 2012)<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.24743","type":"journal-article","created":{"date-parts":[[2011,10,12]],"date-time":"2011-10-12T17:51:55Z","timestamp":1318441915000},"page":"522-529","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":89,"title":["Mortality and the Risk of Malignancy in Autoimmune Liver Diseases: A Population-Based Study in Canterbury, New Zealand"],"prefix":"10.1097","volume":"55","author":[{"given":"Jing Hieng","family":"Ngu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard Blair","family":"Gearry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris Miles","family":"Frampton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine Ann","family":"Malcolm Stedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-21-20241201","doi-asserted-by":"crossref","first-page":"848857","DOI":"10.1053\/gast.1996.v110.pm8608895","article-title":"Prognosis of histological cirrhosis in type 1 autoimmune hepatitis.","volume":"110","author":"Roberts","year":"1996","journal-title":"Gastroenterology"},{"key":"R2-21-20241201","doi-asserted-by":"crossref","first-page":"339341","DOI":"10.1055\/s-2001-13708","article-title":"Longterm management and prognosis of autoimmune hepatitis (AIH): a single center experience.","volume":"39","author":"Kanzler","year":"2001","journal-title":"Z Gastroenterol"},{"key":"R3-21-20241201","doi-asserted-by":"crossref","first-page":"10511057","DOI":"10.1111\/j.1365-2036.2006.03104.x","article-title":"Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study.","volume":"24","author":"Floreani","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R4-21-20241201","doi-asserted-by":"crossref","first-page":"19801989","DOI":"10.1053\/j.gastro.2011.02.065","article-title":"Longterm outcomes of patients with autoimmune hepatitis managed at a nontransplant center.","volume":"140","author":"Hoeroldt","year":"2011","journal-title":"Gastroenterology"},{"key":"R5-21-20241201","doi-asserted-by":"crossref","first-page":"541543","DOI":"10.1136\/jcp.35.5.541","article-title":"Primary biliary cirrhosis: an increased incidence of extrahepatic malignancies?","volume":"35","author":"Mills","year":"1982","journal-title":"J Clin Pathol"},{"key":"R6-21-20241201","doi-asserted-by":"crossref","first-page":"15971598","DOI":"10.1136\/bmj.291.6509.1597","article-title":"Breast cancer in women with primary biliary cirrhosis.","volume":"291","author":"Goudie","year":"1985","journal-title":"Br Med J"},{"key":"R7-21-20241201","doi-asserted-by":"crossref","first-page":"10751078","DOI":"10.1016\/0002-9343(84)90861-1","article-title":"Malignancy in primary biliary cirrhosis. High incidence of breast cancer in affected women.","volume":"76","author":"Wolke","year":"1984","journal-title":"Am J Med"},{"key":"R8-21-20241201","doi-asserted-by":"crossref","first-page":"14251428","DOI":"10.1002\/hep.510290501","article-title":"Hepatic and extrahepatic malignancies in primary biliary cirrhosis.","volume":"29","author":"Floreani","year":"1999","journal-title":"Hepatology"},{"key":"R9-21-20241201","doi-asserted-by":"crossref","first-page":"756760","DOI":"10.1136\/gut.45.5.756","article-title":"Cancer risk in primary biliary cirrhosis: a study in northern England.","volume":"45","author":"Howel","year":"1999","journal-title":"Gut"},{"key":"R10-21-20241201","doi-asserted-by":"crossref","first-page":"11311137","DOI":"10.1002\/hep.21795","article-title":"Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a populationbased cohort study.","volume":"46","author":"Jackson","year":"2007","journal-title":"Hepatology"},{"key":"R11-21-20241201","doi-asserted-by":"crossref","first-page":"361368","DOI":"10.1111\/j.1478-3231.2010.02366.x","article-title":"A 35year followup of a large cohort of patients with primary biliary cirrhosis seen at a single centre.","volume":"31","author":"Floreani","year":"2011","journal-title":"Liver Int"},{"key":"R12-21-20241201","doi-asserted-by":"crossref","first-page":"10441051","DOI":"10.1053\/gast.2002.36027","article-title":"Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: followup for up to 28 years.","volume":"123","author":"Prince","year":"2002","journal-title":"Gastroenterology"},{"key":"R13-21-20241201","doi-asserted-by":"crossref","first-page":"865870","DOI":"10.1136\/gut.2003.023937","article-title":"Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort.","volume":"53","author":"Prince","year":"2004","journal-title":"Gut"},{"key":"R14-21-20241201","doi-asserted-by":"crossref","first-page":"388393","DOI":"10.1016\/j.jhep.2008.08.022","article-title":"Hepatic and extrahepatic malignancies in autoimmune hepatitis. A longterm followup in 473 Swedish patients.","volume":"50","author":"Werner","year":"2009","journal-title":"J Hepatol"},{"key":"R15-21-20241201","doi-asserted-by":"crossref","first-page":"16811686","DOI":"10.1111\/j.1440-1746.2010.06384.x","article-title":"Populationbased epidemiology study of autoimmune hepatitis: a disease of older women?","volume":"25","author":"Ngu","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"R16-21-20241201","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.cgh.2011.08.027","article-title":"Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis.","volume":"9","author":"Ngu","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R17-21-20241201","first-page":"A177","article-title":"Primary biliary cirrhosis in Canterbury, New Zealand: a populationbased study.","volume":"25","author":"Ngu","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"R19-21-20241201","doi-asserted-by":"crossref","first-page":"936943","DOI":"10.1097\/01.mib.0000231572.88806.b9","article-title":"High incidence of Crohns disease in Canterbury, New Zealand: results of an epidemiologic study.","volume":"12","author":"Gearry","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"R20-21-20241201","doi-asserted-by":"crossref","first-page":"929938","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis.","volume":"31","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"R21-21-20241201","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1055\/s-2007-1007179","article-title":"The geoepidemiology of primary biliary cirrhosis.","volume":"17","author":"Metcalf","year":"1997","journal-title":"Sem Liver Dis"},{"key":"R22-21-20241201","doi-asserted-by":"crossref","first-page":"13641369","DOI":"10.1016\/j.gastro.2003.07.011","article-title":"Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community.","volume":"125","author":"Bambha","year":"2003","journal-title":"Gastroenterology"},{"key":"R23-21-20241201","doi-asserted-by":"crossref","first-page":"381386","DOI":"10.1002\/sim.4780020310","article-title":"A comparison of two methods for calculating expected mortality.","volume":"2","author":"Hartz","year":"1983","journal-title":"Stat Med"},{"key":"R24-21-20241201","first-page":"10051012","article-title":"Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse.","volume":"102","author":"MontanoLoza","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R25-21-20241201","doi-asserted-by":"crossref","first-page":"11981206","DOI":"10.1053\/j.gastro.2010.06.046","article-title":"Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis.","volume":"139","author":"Manns","year":"2010","journal-title":"Gastroenterology"},{"key":"R26-21-20241201","doi-asserted-by":"crossref","first-page":"939944","DOI":"10.1016\/j.jhep.2008.02.017","article-title":"Incidence and mortality of primary sclerosing cholangitis in the UK: a populationbased cohort study.","volume":"48","author":"Card","year":"2008","journal-title":"J Hepatol"},{"key":"R27-21-20241201","doi-asserted-by":"crossref","first-page":"18841892","DOI":"10.1002\/hep.23210","article-title":"Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: a populationbased study.","volume":"50","author":"Myers","year":"2009","journal-title":"Hepatology"},{"key":"R28-21-20241201","first-page":"361368","article-title":"A 35year followup of a large cohort of patients with primary biliary cirrhosis seen at a single centre.","volume":"3","author":"Floreani","year":"2011","journal-title":"Liver Int"},{"key":"R29-21-20241201","doi-asserted-by":"crossref","first-page":"321327","DOI":"10.1016\/S0168-8278(01)00288-4","article-title":"Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.","volume":"36","author":"Bergquist","year":"2002","journal-title":"J Hepatol"},{"key":"R30-21-20241201","first-page":"101104","article-title":"Cancer risk in primary biliary cirrhosis: a populationbased study from Sweden.","volume":"20","author":"Loof","year":"1994","journal-title":"Hepatology"},{"key":"R31-21-20241201","doi-asserted-by":"crossref","first-page":"13961398","DOI":"10.1002\/hep.510290511","article-title":"Incidence of cancer in primary biliary cirrhosis: the Mayo experience.","volume":"29","author":"Nijhawan","year":"1999","journal-title":"Hepatology"},{"key":"R32-21-20241201","doi-asserted-by":"crossref","first-page":"7783","DOI":"10.3109\/00365529709025067","article-title":"Primary biliary cirrhosis in the Netherlands. An analysis of associated diseases, cardiovascular risk, and malignancies on the basis of mortality figures.","volume":"32","author":"Van Dam","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"R33-21-20241201","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/MEG.0b013e3282f16436","article-title":"Malignancies in primary biliary cirrhosis.","volume":"20","author":"Piscaglia","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R34-21-20241201","doi-asserted-by":"crossref","first-page":"11721178","DOI":"10.1053\/jhep.2002.33157","article-title":"Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis.","volume":"35","author":"Shibuya","year":"2002","journal-title":"Hepatology"},{"key":"R35-21-20241201","doi-asserted-by":"crossref","first-page":"11621168","DOI":"10.1002\/hep.23095","article-title":"Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers.","volume":"50","author":"Cavazza","year":"2009","journal-title":"Hepatology"},{"key":"R36-21-20241201","first-page":"676678","article-title":"Hepatocellular carcinoma in primary biliary cirrhosis.","volume":"92","author":"Turissini","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"R37-21-20241201","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1002\/hep.1840100110","article-title":"Extrahepatic malignancy following longterm immunosuppressive therapy of severe hepatitis B surface antigennegative chronic active hepatitis.","volume":"10","author":"Wang","year":"1989","journal-title":"Hepatology"},{"key":"R38-21-20241201","doi-asserted-by":"crossref","first-page":"514527","DOI":"10.1111\/j.1365-2796.2008.02029.x","article-title":"Autoimmune and inflammatory disorders and risk of malignant lymphomasan update.","volume":"264","author":"Smedby","year":"2008","journal-title":"J Intern Med"},{"key":"R39-21-20241201","doi-asserted-by":"crossref","first-page":"541550","DOI":"10.1080\/10428190902780677","article-title":"Autoimmunity and hematologic malignancies: associations and mechanisms.","volume":"50","author":"Martin","year":"2009","journal-title":"Leuk Lymphoma"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.24743","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201202000-00021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:47:42Z","timestamp":1733060862000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201202000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.24743","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}